Recent developments and future challenges in immune checkpoint inhibitory cancer treatment

Current Opinion in Oncology
Bas D KosterAlfons J M VAN DEN Eertwegh

Abstract

In this review, we focus on the recent findings and future challenges in cancer treatment with immune checkpoint inhibitors. Major progress has been made in recent years as the first immune checkpoint inhibitors are approved by the US Food and Drug Administration for the treatment of cancer patients. Anticytotoxic T-lymphocyte-associated protein 4 and antiprogrammed death protein 1/programmed death-ligand 1 (PD-L1) monoclonal antibodies are being extensively studied in many different tumor types, often showing impressive response rates, but also a typical serious toxicity profile in the form of auto-immunity. Unfortunately, it is not yet possible to prevent or predict these immune-related adverse events. Studies on mutational load, neo-epitopes, lactate dehydrogenase, PD-L1 expression, and T-cell infiltration suggest that these markers are correlating with efficacy, but have not yet reached the status of a validated biomarker for checkpoint inhibitors. Other immune checkpoints are being investigated and new checkpoint inhibitors are on the brink of being evaluated in clinical trials. The main challenge for the near future will be to predict efficacy of immune checkpoint blockade and to predict and prevent immune-related adverse...Continue Reading

References

Sep 5, 2002·European Journal of Immunology·Creg J WorkmanDario A A Vignali
Mar 18, 2005·Annual Review of Immunology·Rebecca J GreenwaldArlene H Sharpe
May 27, 2008·Nature Reviews. Immunology·Weiping Zou, Lieping Chen
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Dec 15, 2010·Expert Opinion on Therapeutic Targets·Sophie SierroDaniel E Speiser
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J LynchMartin Reck
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Mar 6, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ignacio MeleroPaolo A Ascierto
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 12, 2013·The Journal of Experimental Medicine·Rikke B HolmgaardJames P Allison
Jun 19, 2013·The Oncologist·Leslie A FecherJeffrey S Weber
Jun 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marieke F FransenCornelis J M Melief
Jul 31, 2013·The Journal of Experimental Medicine·Yannick BulliardJennifer L Brogdon
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick A OttCaroline Robert
Feb 4, 2014·Current Opinion in Immunology·Jose Luis Perez-GraciaIgnacio Melero
Mar 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lidia RobertAntoni Ribas
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Apr 3, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aurélien MarabelleRonald Levy
Apr 3, 2014·Cancer Research·J Louise LinesRandolph Noelle
Apr 3, 2014·Cancer Research·Isabelle Le MercierLi Wang
Aug 22, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Min DaiKarl Erik Hellstrom
Oct 18, 2014·International Immunology·George K Philips, Michael Atkins
Oct 30, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roxana S Dronca, Haidong Dong
Nov 15, 2014·Cancer Discovery·Jennifer A WargoKeith T Flaherty
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Dec 24, 2014·Nature Reviews. Immunology·Linh T Nguyen, Pamela S Ohashi
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Mar 11, 2015·Nature·Christina Twyman-Saint VictorAndy J Minn
Apr 10, 2015·British Journal of Cancer·B Homet Moreno, A Ribas
Apr 14, 2015·The Journal of Clinical Investigation·Joe-Marc ChauvinHassane M Zarour

❮ Previous
Next ❯

Citations

Mar 11, 2017·Current Opinion in Oncology·Patrick Terheyden, Jürgen C Becker
Dec 4, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Marcela Montes de OcaChristian R Engwerda
Nov 15, 2017·Journal of Clinical Pharmacology·Anna E KershBrian P Pollack
Feb 17, 2018·Cell Death & Disease·Maria Michela D'AloiaMaurizio Alimandi
Apr 5, 2019·Cancer Immunology, Immunotherapy : CII·Jossie RotmanTanja D de Gruijl
Jul 13, 2016·Advances in Anatomic Pathology·Megan L TroxellNeeraja Kambham
Aug 5, 2017·BioMed Research International·Giulia VialeGiuseppe Curigliano
Nov 22, 2018·Frontiers in Immunology·Gilberto FilaciAntonio Di Biagio
May 19, 2017·Journal for Immunotherapy of Cancer·Sacha GnjaticLisa H Butterfield
Oct 17, 2017·Frontiers in Oncology·Charissa A C JessurunRosalie M Luiten
Mar 13, 2021·Advanced Healthcare Materials·Mengying HeHuabing Chen
Jun 20, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Annamaria MascoloAnnalisa Capuano

❮ Previous
Next ❯

Software Mentioned

Cell Genesys

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jean-Charles SoriaScott Gettinger
Journal for Immunotherapy of Cancer
Leila KhojaAnthony M Joshua
© 2021 Meta ULC. All rights reserved